Iovate claims upheld
This article was originally published in The Tan Sheet
Executive Summary
The Electronic Retailing Self-Regulation Program says July 18 Iovate Health Sciences' general product performance claims for its JointMD Joint Relief supplement are substantiated, but the firm must discontinue other claims. ESRP determines Mississauga, Ontario-based Iovate provides reasonable basis for its claims the product's primary ingredient begins working faster than glucosamine. However, Iovate's claims the product works 300% faster than maximum strength glucosamine must be discontinued. WellNx Life Sciences, a competing firm also based in Mississauga, challenged Iovate's claims in the self-regulatory forum...
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.